Literature DB >> 22123166

Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence.

C J Hillard1, K M Weinlander, K L Stuhr.   

Abstract

The endocannabinoid signaling system is a widespread, neuromodulatory system in brain and is also widely utilized in the periphery to modulate metabolic functions and the immune system. Preclinical data demonstrate that endocannabinoid signaling is an important stress buffer and modulates emotional and cognitive functions. These data suggest the hypothesis that endocannabinoid signaling could be dysfunctional in a number of mental disorders. Genetic polymorphisms in the human genes for two important proteins of the endocannabinoid signaling system, the CB1 cannabinoid receptor (CB1R) and fatty acid amide hydrolase (FAAH), have been explored in the context of normal and pathological conditions. In the case of the gene for FAAH, the mechanistic relationships among the common genetic polymorphism, the expression of the FAAH protein, and its likely impact on endocannabinoid signaling are understood. However, multiple polymorphisms in the gene for the CB1R occur and are associated with human phenotypic differences without an understanding of the functional relationships among the gene, mRNA, protein, and protein function. The endocannabinoid ligands are found in the circulation, and several studies have identified changes in their concentrations under various conditions. These data are reviewed for the purpose of generating hypotheses and to encourage further studies in this very interesting and important area. Copyright Â
© 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22123166      PMCID: PMC3288440          DOI: 10.1016/j.neuroscience.2011.11.020

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  231 in total

1.  The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction.

Authors:  Jonathan M Flanagan; Alexandra L Gerber; Jean Lud Cadet; Ernest Beutler; Jack C Sipe
Journal:  Hum Genet       Date:  2006-09-14       Impact factor: 4.132

Review 2.  Involvement of the endocannabinoid system in drug addiction.

Authors:  Rafael Maldonado; Olga Valverde; Fernando Berrendero
Journal:  Trends Neurosci       Date:  2006-02-17       Impact factor: 13.837

Review 3.  Imaging brain response to reward in addictive disorders.

Authors:  Daniel W Hommer; James M Bjork; Jodi M Gilman
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

Review 4.  The evolving genetic foundations of eating disorders.

Authors:  K L Klump; W H Kaye; M Strober
Journal:  Psychiatr Clin North Am       Date:  2001-06

5.  Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa.

Authors:  Nathalie Gérard; Guido Pieters; Karolien Goffin; Guy Bormans; Koen Van Laere
Journal:  Biol Psychiatry       Date:  2011-06-29       Impact factor: 13.382

6.  Genetic and environmental contributions to cannabis dependence in a national young adult twin sample.

Authors:  M T Lynskey; A C Heath; E C Nelson; K K Bucholz; P A F Madden; W S Slutske; D J Statham; N G Martin
Journal:  Psychol Med       Date:  2002-02       Impact factor: 7.723

7.  Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.

Authors:  F Markus Leweke; Andrea Giuffrida; Dagmar Koethe; Daniela Schreiber; Brit M Nolden; Laura Kranaster; Miriam A Neatby; Miriam Schneider; Christoph W Gerth; Martin Hellmich; Joachim Klosterkötter; Daniele Piomelli
Journal:  Schizophr Res       Date:  2007-06-13       Impact factor: 4.939

8.  Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence.

Authors:  Arpana Agrawal; Leah Wetherill; Danielle M Dick; Xiaoling Xuei; Anthony Hinrichs; Victor Hesselbrock; John Kramer; John I Nurnberger; Marc Schuckit; Laura J Bierut; Howard J Edenberg; Tatiana Foroud
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-07-05       Impact factor: 3.568

9.  Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver.

Authors:  Won-il Jeong; Douglas Osei-Hyiaman; Ogyi Park; Jie Liu; Sándor Bátkai; Partha Mukhopadhyay; Norio Horiguchi; Judith Harvey-White; Giovanni Marsicano; Beat Lutz; Bin Gao; George Kunos
Journal:  Cell Metab       Date:  2008-03       Impact factor: 27.287

10.  The incentive salience of alcohol: translating the effects of genetic variant in CNR1.

Authors:  Kent E Hutchison; Heather Haughey; Michelle Niculescu; Joe Schacht; Alan Kaiser; Jerry Stitzel; William J Horton; Francesca Filbey
Journal:  Arch Gen Psychiatry       Date:  2008-07
View more
  63 in total

Review 1.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

2.  Quantification of 24 circulating endocannabinoids, endocannabinoid-related compounds, and their phospholipid precursors in human plasma by UHPLC-MS/MS.

Authors:  Waldemar Röhrig; Susanne Achenbach; Birgit Deutsch; Monika Pischetsrieder
Journal:  J Lipid Res       Date:  2019-06-24       Impact factor: 5.922

3.  Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide).

Authors:  Erin C Hanlon
Journal:  Psychoneuroendocrinology       Date:  2019-10-04       Impact factor: 4.905

4.  Role of CNR1 polymorphisms in moderating the effects of psychosocial adversity on impulsivity in adolescents.

Authors:  Arlette F Buchmann; Erika Hohm; Stephanie H Witt; Dorothea Blomeyer; Christine Jennen-Steinmetz; Martin H Schmidt; Günter Esser; Tobias Banaschewski; Daniel Brandeis; Manfred Laucht
Journal:  J Neural Transm (Vienna)       Date:  2014-07-01       Impact factor: 3.575

Review 5.  Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?

Authors:  Cecilia J Hillard
Journal:  Neuropsychopharmacology       Date:  2017-06-27       Impact factor: 7.853

Review 6.  Neurobiological Interactions Between Stress and the Endocannabinoid System.

Authors:  Maria Morena; Sachin Patel; Jaideep S Bains; Matthew N Hill
Journal:  Neuropsychopharmacology       Date:  2015-06-12       Impact factor: 7.853

7.  2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons.

Authors:  Alvaro Llorente-Berzal; Ana Luisa B Terzian; Vincenzo di Marzo; Vincenzo Micale; Maria Paz Viveros; Carsten T Wotjak
Journal:  Psychopharmacology (Berl)       Date:  2015-03-28       Impact factor: 4.530

Review 8.  Pathological Overeating: Emerging Evidence for a Compulsivity Construct.

Authors:  Catherine F Moore; Valentina Sabino; George F Koob; Pietro Cottone
Journal:  Neuropsychopharmacology       Date:  2016-12-06       Impact factor: 7.853

Review 9.  Stress regulates endocannabinoid-CB1 receptor signaling.

Authors:  Cecilia J Hillard
Journal:  Semin Immunol       Date:  2014-05-29       Impact factor: 11.130

Review 10.  Endogenous cannabinoid signaling at inhibitory interneurons.

Authors:  Thomas J Younts; Pablo E Castillo
Journal:  Curr Opin Neurobiol       Date:  2013-12-28       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.